A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic. New Griffith University research, published in Nature Communications , has been testing the efficacy of delivering a COVID-19 vaccine via the nasal passages. Professor Suresh Mahalingam from Griffith's Institute for Biomedicine and Glycomics has been working on this research for the past four years.
This is a live attenuated intranasal vaccine, called CDO-7N-1, designed to be administered intranasally, thereby inducing potential mucosal immunity as well as systemic immunity with just a single dose." Suresh Mahalingam, Professor, Institute for Biomedicine and Glycomics, Griffith University Mahalingam added, "The vaccine induces strong memory responses in the nasal mucosa offering long-term protection for up to a year or more. "It's been designed to be administered as single dose, ideally as a booster vaccine, as a safe alternative to needles with no adverse reactions in the short or long term.
" Live-attenuated vaccines offer several significant advantages over other vaccine approaches. Related Stories Experimental malaria vaccine shows promise in protecting pregnant women Playing video games for a couple of hours a day can improve mental health Novel vaccination strategy shows promise in boosting immunity and controlling influenza spread in pigs They induce potent and long-lived humoral and cellular immunity, often with j.